Risk Factors for Cisplatin-Associated Ototoxicity in Pediatric Oncology Patients

dc.contributor.authorYancey, Allison
dc.contributor.authorHarris, Michael S.
dc.contributor.authorEgbelakin, Akinbode
dc.contributor.authorGilbert, Jaimie
dc.contributor.authorPisoni, David B.
dc.contributor.authorRenbarger, Jamie
dc.contributor.departmentPediatrics, School of Medicine
dc.date.accessioned2025-07-09T13:40:13Z
dc.date.available2025-07-09T13:40:13Z
dc.date.issued2012
dc.description.abstractBackground: Cisplatin is an effective chemotherapy agent against several pediatric malignancies. One of its side effects is irreversible sensorineural hearing damage that is highly variable with a reported incidence of 22-70%. The aim of this study was to evaluate the incidence and identify clinical predictors of cisplatin-related ototoxicity. Procedures: We performed a retrospective chart review of 102 pediatric patients who had completed cisplatin therapy for osteosarcoma, neuroblastoma, hepatoblastoma, or germ cell tumor. Patients were diagnosed at Riley Hospital for Children between January 1995 and June 2008, were less than 18 years old at diagnosis, and had normal hearing prior to therapy. Audiograms were scored using the Brock scale (0-4), a validated grading system for cisplatin-related hearing loss. Results: Forty-two percent of the patients experienced hearing loss and 28% had moderate to severe ototoxicity (Brock score ≥2). Males were at significantly greater risk for developing hearing loss than were females (P = 0.005, OR 4.812). Age at cancer diagnosis was inversely related to severity of ototoxicity. Patients who suffered Brock grade 3 ototoxicity had a mean age of 4.5 years versus 11.5 years and 7.2 years for grades 1 and 2, respectively (P = 0.02). Cumulative cisplatin dose was also identified as a risk factor for development of ototoxicity (P = 0.03). Conclusions: Gender and cumulative dose are important clinical biomarkers of cisplatin ototoxicity. Severity of ototoxicity may be inversely related to age at time of exposure, with very young patients exhibiting higher grades of hearing loss following cisplatin therapy.
dc.eprint.versionAuthor's manuscript
dc.identifier.citationYancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer. 2012;59(1):144-148. doi:10.1002/pbc.24138
dc.identifier.urihttps://hdl.handle.net/1805/49280
dc.language.isoen_US
dc.publisherWiley
dc.relation.isversionof10.1002/pbc.24138
dc.relation.journalPediatric Blood & Cancer
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectCisplatin
dc.subjectHearing loss
dc.subjectOtotoxicity
dc.subjectRisk factors
dc.titleRisk Factors for Cisplatin-Associated Ototoxicity in Pediatric Oncology Patients
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Yancey2012Risk-AAM.pdf
Size:
200.66 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: